Tenaya Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Tenaya Therapeutics Inc 's ROA in the second quarter of 2026?
Tenaya Therapeutics Inc recorded a cumulative net loss of $-103 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -82.42%.

However, within the Healthcare sector 706 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4081, from total ROA ranking in the first quarter of 2026 at 4805.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-7.1 %	-6.17 %	34.5 %	-18.67 %	-18.82 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-103	-83	-91	-94	-100
Return On Assets (TTM)	-82.42 %	-65.21 %	-69.96 %	-78.5 %	-79 %
TNYA's Total Ranking	# 4081	# 4805	# 4267	# 4310	# 4380
Total Assets (TTM) in million	113	135	147	105	122
Seq. Total Assets Change	-15.98 %	-8.07 %	39.95 %	-14.06 %	-15.14 %
Seq. Net Income Change	-	-	-	-	-

TNYA's 5 Years Annual ROA >> Back to TNYA Management Effectiveness >> Compare TNYA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 109
Sector	# 707
Overall	# 4164

Return On Assets Statistics
High	Average	Low
-47.44 %	-106.62 %	-286.04 %
		(Dec 31 2021)

Financial Statements
Tenaya Therapeutics Inc 's Assets	$ 113 million	TNYA's Balance sheet
Tenaya Therapeutics Inc 's Income	$ -43 million	Quarterly TNYA's Income Statement
TNYA's Income by Division		See TNYA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2020) FY 2021
Y / Y Total Assets Change	34.5 %	-32.51 %	-39.71 %	50.72 %	-
Total Assets in million	147	109	162	268	178
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-91	-111	-124	-124	-38
Annual Return On Assets	-61.66 %	-101.74 %	-76.66 %	-46.06 %	-21.55 %

TNYA's 5 Years Annual ROA >> Back to TNYA Management Effectiveness >> Compare TNYA ROA to its Competitors

More Return On Assets Ratios
TNYA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TNYA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TNYA's Competitors
Subscribers only: Roa for Tenaya Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for TNYA's Customers

You may also want to know
TNYA's Roi	TNYA's Inventory Turnover Ratio	TNYA's Growth Rates	TNYA's Dividend Comparisons
	TNYA's Profitability Ratios	TNYA's Asset Turnover Ratio	TNYA's Dividend Growth
TNYA's Roe	TNYA's Valuation Ratios	TNYA's Financial Strength Ratios	TNYA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-10T17:45:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.